Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14268232 | 1.00 | L3MBTL1 (0.45) | L3MBTL1HTTALDH1A1CHRM3KMT2A | |
| SCHEMBL22198680 | 0.89 | L3MBTL1 (0.34) | L3MBTL1HTT | |
| SCHEMBL24712789 | 0.86 | S1PR1 (0.36) | L3MBTL1HTTDRD2 | |
| SCHEMBL19123569 | 0.84 | L3MBTL1 (0.41) | L3MBTL1HTTALDH1A1CHRM3KMT2A | |
| SCHEMBL23023331 | 0.82 | L3MBTL1 (0.31) | L3MBTL1CHRM3 | |
| SCHEMBL27113500 | 0.81 | L3MBTL1 (0.39) | L3MBTL1HTTALDH1A1CHRM3KMT2A | |
| SCHEMBL26512146 | 0.81 | SPHK2 (0.34) | L3MBTL1HTTCHRM3 | |
| SCHEMBL22063588 | 0.81 | CHRM3 (0.34) | L3MBTL1CHRM3KMT2AMEN1 | |
| SCHEMBL26512063 | 0.81 | DRD2 (0.37) | HTTDRD2 | |
| SCHEMBL24359069 | 0.80 | CRHR1 (0.30) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | 280 Bio, Inc (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2022247770-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海璎黎药业有限公司 | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | NRAS, KRAS, RAB8A | L3MBTL1 4051/4885HTT 1060/4885ALDH1A1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.